BACKGROUND: Safe, accurate methods to reliably measure circulating red blood cell (RBC) kinetics are critical tools to investigate pathophysiology and therapy of anemia, including hemolytic anemias. This study documents the ability of a method using biotin-labeled RBCs (BioRBCs) to measure RBC survival (RCS) shortened by coating with a highly purified monomeric immunoglobulin G antibody to D antigen. STUDY DESIGN AND METHODS: Autologous RBCs from 10 healthy D+ subjects were labeled with either biotin or (51) Cr (reference method), coated (opsonized) either lightly (n = 4) or heavily (n = 6) with anti-D, and transfused. RCS was determined for BioRBCs and for (51) Cr independently as assessed by three variables: 1) posttransfusion recovery at 24 hours (PTR(24) ) for short-term RCS; 2) time to 50% decrease of the label (T(50) ), and 3) mean potential life span (MPL) for long-term RCS. RESULTS: BioRBCs tracked both normal and shortened RCS accurately relative to (51) Cr. For lightly coated RBCs, mean PTR(24) , T(50) , and MPL results were not different between BioRBCs and (51) Cr. For heavily coated RBCs, both short-term and long-term RCS were shortened by approximately 17 and 50%, respectively. Mean PTR(24) by BioRBCs (84 ± 18%) was not different from (51) Cr (81 ± 10%); mean T(50) by BioRBCs (23 ± 17 days) was not different from (51) Cr (22 ± 18 days). CONCLUSION: RCS shortened by coating with anti-D can be accurately measured by BioRBCs. We speculate that BioRBCs will be useful for studying RCS in conditions involving accelerated removal of RBCs including allo- and autoimmune hemolytic anemias.
BACKGROUND: Safe, accurate methods to reliably measure circulating red blood cell (RBC) kinetics are critical tools to investigate pathophysiology and therapy of anemia, including hemolytic anemias. This study documents the ability of a method using biotin-labeled RBCs (BioRBCs) to measure RBC survival (RCS) shortened by coating with a highly purified monomeric immunoglobulin G antibody to D antigen. STUDY DESIGN AND METHODS: Autologous RBCs from 10 healthy D+ subjects were labeled with either biotin or (51) Cr (reference method), coated (opsonized) either lightly (n = 4) or heavily (n = 6) with anti-D, and transfused. RCS was determined for BioRBCs and for (51) Cr independently as assessed by three variables: 1) posttransfusion recovery at 24 hours (PTR(24) ) for short-term RCS; 2) time to 50% decrease of the label (T(50) ), and 3) mean potential life span (MPL) for long-term RCS. RESULTS: BioRBCs tracked both normal and shortened RCS accurately relative to (51) Cr. For lightly coated RBCs, mean PTR(24) , T(50) , and MPL results were not different between BioRBCs and (51) Cr. For heavily coated RBCs, both short-term and long-term RCS were shortened by approximately 17 and 50%, respectively. Mean PTR(24) by BioRBCs (84 ± 18%) was not different from (51) Cr (81 ± 10%); mean T(50) by BioRBCs (23 ± 17 days) was not different from (51) Cr (22 ± 18 days). CONCLUSION: RCS shortened by coating with anti-D can be accurately measured by BioRBCs. We speculate that BioRBCs will be useful for studying RCS in conditions involving accelerated removal of RBCs including allo- and autoimmune hemolytic anemias.
Authors: I R Hudson; I A Cavill; A Cooke; B M Holland; T G Hoy; D Trevett; T L Turner; C A Wardrop Journal: Pediatr Res Date: 1990-09 Impact factor: 3.756
Authors: Donald M Mock; Nell I Matthews; Shan Zhu; Ronald G Strauss; Robert L Schmidt; Demet Nalbant; Gretchen A Cress; John A Widness Journal: Transfusion Date: 2010-11-09 Impact factor: 3.157
Authors: G Hoffmann-Fezer; J Mysliwietz; W Mörtlbauer; H J Zeitler; E Eberle; U Hönle; S Thierfelder Journal: Ann Hematol Date: 1993-08 Impact factor: 3.673
Authors: Donald M Mock; Demet Nalbant; Svetlana V Kyosseva; Robert L Schmidt; Guohua An; Nell I Matthews; Alexander P J Vlaar; Robin van Bruggen; Dirk de Korte; Ronald G Strauss; José A Cancelas; Robert S Franco; Peter Veng-Pedersen; John A Widness Journal: Transfusion Date: 2018-05-16 Impact factor: 3.157
Authors: Donald M Mock; John A Widness; Peter Veng-Pedersen; Ronald G Strauss; Jose A Cancelas; Robert M Cohen; Christopher J Lindsell; Robert S Franco Journal: Transfus Med Rev Date: 2014-04-05
Authors: Demet Nalbant; José A Cancelas; Donald M Mock; Svetlana V Kyosseva; Robert L Schmidt; Gretchen A Cress; M Bridget Zimmerman; Ronald G Strauss; John A Widness Journal: Transfusion Date: 2017-11-29 Impact factor: 3.157
Authors: Donald M Mock; Sean R Stowell; Robert S Franco; Svetlana V Kyosseva; Demet Nalbant; Robert L Schmidt; Gretchen A Cress; Ronald G Strauss; José A Cancelas; Melissa von Goetz; Anne K North; John A Widness Journal: Transfusion Date: 2022-03-11 Impact factor: 3.337